CJC-1295 + Ipamorelin
Popular GHRH + ghrelin-mimetic pairing; rationale is physiological, but combination trials don't exist.
Not FDA-approved. Compounded; both components unapproved and WADA-prohibited. This page describes research and public discussion; it is not a recommendation to use.
Overview
Pairing a GHRH analogue with a GHS-R agonist can synergistically increase GH release in pharmacology studies of related compounds. The specific combination has not been clinically tested.
Blend components
Mechanism of action
GHRH receptor stimulation (CJC) plus ghrelin-receptor stimulation (ipamorelin).
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Online protocols D Anecdotal / community | ~100 mcg each | Nightly | 8–12 weeks | Subcutaneous |
Clinical trials & studies
No studies of this specific combination have been published.
Safety
Side effects
- Flushing, water retention, hunger
Contraindications
- Active cancer
- Pregnancy
Interactions
- Diabetes medication
Long-term safety
Unknown.
Regulatory status
Unapproved / research
Compounded; both components unapproved and WADA-prohibited.